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RAPID PRECLINICAL SCREENING OF CHEMOTHERAPEUTIC AGENTS
EFFECTIVE IN COMBINATION WITH IMMUNOTHERAPY
Lucas, P.J., Sivarapatna, A., Wang, J., Gress, R.E. National Institutes of
Health, Bethesda, MD
Therapeutic alternatives are extremely limited for patients with
disease relapse following allogeneic marrow transplantation. One ap-
proach has been to intensify the immunotherapy of transplantation
by infusion of lymphocytes upon disease relapse (delayed lymphocyte
infusion, DLI). Administration of DLI can be limited by graft versus
hostdisease, and its effectivenessby tumor accessibility, suppressive lo-
cal tumor environment, low tumor antigenicity, and systemic immune
tolerance. Recent studies have shown that certain chemotherapeutic
agents, especially those with knownmolecular targets, can be effective
in combinationwithDLI to eliminate residual tumor.Toassess the ef-
fectiveness of targeted chemotherapeutic agents in conjunction with
DLI, we have developed a series of in vitro and in vivo murine assays
to screen potential agents for combinationDLI therapy. In vitro tissue
culture with flow cytometric analysis using annexin, propidium iodine,
and CFSEmarkers is used to establish tumor susceptibility and effec-
tive dose for each chemotherapeutic agent.Characterizationof adverse
in vivo effects on relevant immune effector and regulatory populations,
such asmemory and na€ıveT, antigen presenting, NK andTreg cells is
then assessed using drug titration in a thymectomizedmousemodel to
avoid the variable of thymic derivedT cell renewal. Finally, optimized
drug concentrations are used in an allogeneic graft versus tumor
(GVT) model to screen for additive or synergistic effects on tumor
growth in conjunction with DLI. Using these screening methods we
have been able to rapidly identify useful chemotherapeutic agents,
and establish drug concentrations capable of improving survival over
GVT effects associated with DLI alone. In addition, in vitro drug
effectiveness, as measured by cell membrane injury, cell death and
decreased cell proliferation, has been an effective tool to predict
in vivo anti-tumor responses.513
TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST
DISEASE WITH BASILIXIMAB AND ETANERCEPT IN EARLY PERIOD
Tan, Y., Luo, Y., Shi, J., He, J., Zhao, Y., Lai, X., Zheng, W., Sun, J.,
Zheng, Y., Cai, Z., Lin,M., Huang, H. The First Affiliated Hospital, Zhe-
jiang University School of Medicine, Hangzhou, Zhejiang Province, China
Background: Severe acute graft-versus-host disease (aGVHD) is
a life-threatening complication after allogeneic hematopoietic stem
cell transplantation (allo-HSCT). Steroid-resistant aGVHD(SR-
aGVHD) is especially associated with a high incidence of mortality.
Methods:We performed a prospective study in treatment of grades
III-IV SR-aGVHD in early period with a combination of anti-cyto-
kine therapy composed of IL-2 receptor antibody (basiliximab) and
TNF-receptor fusion protein (etanercept) from June 2009 to Agust
2010. Seven patients experienced grade IV SR-aGVHD (skin in-
volved in seven patients, gastro-intestinal involved in six patients,
liver involved in four patients). The median age was 23 years (range
11-48). Donor types were HLA-matched related (n 5 1), HLA-
matched unrelated (n 5 2), and haploidentical related (n 5 4).
Anti-cytokine therapy consisted of intravenous basiliximab 20mg
on days 1, 4, 8, 15, and etanercept 25 mg subcutaneous twice
a week for 4 weeks, followed by once weekly for 4 more weeks.
Results: All patients (100%) achieved complete remission. Five of 7
(71.4%) patients are currently alive with a median follow-up of 163
(80–348) days after transplantation, and a median follow-up of 121
(48–321) days after Anti-cytokine therapy. Only two patients died
of pulmonary infection and cardiac arrest. In our retrospectivly
studied in twenty-three patients with SR-aGVHD who reveiving
allo-HSCT from HLA-matched related donor (n 5 1), HLA-mis-
matched related donor (n 5 1),HLA-matched unrelated donor
(n 5 6), HLA-misatched unrelated donor (n 5 15), the treatment
of SR-aGVHD included high dose methylprednisolone, anti-thy-
mocyte globulin, basiliximab or etanercept, respectively. Only five
(21.7%) patients achieved CR and two(8.69%) achieved partial
remission. Only five of 23 (21.7%) patients are currently alive with
a median follow-up of 52 (32–3697) days after transplantation.The
incidence of treatment-related mortality (TRM) was 78.3%. The
cause were infectious complications and organ failure.Conclusion: Inflammatory cytokines, IL-2 and TNF-a, play critical
roles in the pathological of GVHD, and may be effective targets for
therapy. Our data suggested that the combination of basiliximab and
etanercept is well tolerated and can induce a high response rate, high
survival rate with low incidence of TRM in patients with severe SR-
aGVHD in early period, particularly in sever GrmonaryI aGVHD.514
MYELOABLATIVE UNRELATED CORD BLOOD TRANSPLANTATION FROM
GRAFTS WITH THREE HLA ANTIGEN MISMATCHES RESULTED IN SUPE-
RIOR OUTCOMES FOR PATIENTS WITH DE NOVO ACUTE LEUKEMIAS
Tsukada, N.1, Takahashi, S.1, Ooi, J.1, Kato, S.1, Kawakita, T.1,
Nagamura, F.1, Yamaguchi, T.2, Tojo, A.1, Asano, S.1 1 Institute of
Medical Science, University of Tokyo, Tokyo, Japan; 2University of Tokyo,
Tokyo, Japan
Westudied the clinicaloutcomesof 87 adultswithdenovoacute leu-
kemias who received unrelated cord blood transplantation (CBT) after
myeloablative conditioning. Between August 1998 and July 2008, 55
patients with acute myelogenous leukemia (AML) and 32 patients
with acute lymphoblastic leukemia (ALL) were treated with unrelated
CBT. All patients received 4 fractionated 12 Gy total body irradiation
(TBI) and chemotherapy asmyeloablative conditioningandcyclospor-
ine plus short termmethotrexate as graft-versus-host disease (GVHD)
prophylaxis. The median age was 38 years and the median number of
nucleated cells was 2.38 x 107/kg. 16 patients were transplanted not
in complete remission (CR). t(9;22) and 11q23 abnormalities were
found in nine and seven, respectively. All patients received a single
cord blood unit and grafts were selected from at least 4/6 serologically
matched units in the Japan Cord Blood BankNetwork. Variables con-
sidered in statistical analyses were age, gender, diagnosis, disease status
at CBT, disease risk, cytogenetic subgroups, total nucleated cell
(TNC) dose, sex mismatches, ABO mismatches, HLA mismatches
(A andBby low resolution,DRB1by high resolution), and blood levels
of cyclosporine. With a median follow-up of 42 months (range
13-120), the probability of disease free survival (DFS) at 5 years was
67.1% (95%CI: 57.0-77.2%). The 5-year cumulative incidence of re-
lapse was 23.1% (95%CI: 13.7-32.5%). In multivariate analysis, the
risk factor identified for both DFS and the incidence of relapse was
the numbers of HLA mismatches. The probability of DFS and the
cumulative incidence of relapse in the subset of three HLA antigen
mismatches (n 5 25) were 89.6% and 9.9%, respectively. Several re-
ports have shown thatHLAmatchedCBT resulted in better outcome,
but our study revealed superior outcome in recipients of grafts with
three HLA antigen mismatches. Although this is a result from a Japa-
nese single institute, we suggest that CBT from grafts with threeHLA
antigenmismatchesmay improve outcomes by reducing the incidence
of relapse without increasing treatment related mortality (TRM) in
adult patients with de novo acute leukemias.515
SINGLE DOSE ADMINISTRATION OF ECP TREATED CELLS PRIOR TO
TRANSPLANTATION SIGNIFICANTLY INCREASES SURVIVAL IN A MHC-
MISMATCHED MODEL OF ACUTE GVHD
Florek, M., Sega, E.I., Leveson-Gower, D.B., Gill, S., Mueller, A.M.S.,
Negrin, R.S. Stanford University, Stanford, CA
Extracorporeal photophoresis (ECP) has shown promise as a ther-
apeutic modality in treating steroid-resistant chronic and acute
GvHD. The way ECP mediates its effect has not been clearly eluci-
dated, but some of the proposed mechanisms include impaired mat-
uration of dendritic cells and reduced antigen presentation induced
by apoptotic cells, as well as increased regulatory T (Treg) cells.
We have developed a pre-emptive murine model of ECP to inhibit
the initiation phase of acute GvHD and improve survival.
Methods: Apoptosis was induced by ECP using 8-Methoxypsoralen
and UVA light (UVAR light set, Therakos). Two days prior to bone
marrow transplantation (BMT), 10^7 syngeneic (BalbC;H2-d) or allo-
geneic (C57BL6;H2-b) splenocytes treatedwithECPwere infused into
BalbC recipients. To induce acute GvHD mice received 0.75x10^6
conventional T cells (Tcon) and 5x10^6 T cell depleted bone marrow
from C57BL6 (H2-b). Animals were followed for survival, and GvHD
was scoredusing standard criteria. In someexperiments,Tconwerede-
rived from luciferase-transgenic animals, allowing for quantification of
T cell proliferation using bioluminescent imaging (BLI).
S338 Poster Session IIResults:A single dose of pre-emptive ECP treated splenocytes led to
a significant survival benefit (median survival 27 versus 52 days, p\
0.0001). Re-isolation experiments on day 7 after BMT showed an in-
crease in host Treg in peripheral and mesenteric lymph nodes,
whereas donor Treg were similar in both groups. However, Tcon
proliferation was not significantly impacted, as quantified by BLI.
Using pulsed BrdU labeling no proliferation of host Treg was seen
after transplantation. Also, intracellular staining and analysis of
serum cytokine levels to characterize Th1/Th2 polarization of T
cells revealed no differences at day 7. Importantly, preliminary
experiments showed no alteration in graft versus tumor effect. In
summary, a single dose of apoptotic cells prior to transplantation
led to a significant survival benefit. Whether this effect is related
to the relative sparing of host-Tregs remains to be determined.
However, the mechanism does not appear to be related to reduced
T cell proliferation. Other avenues to be explored include further
studies of cellular mechanism, e.g. maturation status of host APC,
as well as evaluating multiple administration doses to further
improve outcome. Pre-emptive ECP of host cells prior to BMT
may be a clinically relevant strategy to ameliorate acute GvHD.516
GENE EXPRESSION IN CD4+ T CELLS OF PATIENTSWITH ANDWITHOUT
CHRONIC GRAFT-VS-HOST DISEASE (CGVHD)
Tabellini, L.1, Fan,W.1, Zhao, L.P.1, Bumgarner, T.E.1, Flowers, M.E.1,
Grogan, B.M.1, Warren, H.E.1,2, Lee, S.J.1,2, Martin, P.J.1,2,
Hansen, J.A.1,2 1Fred Hutchinson Cancer Research Center, Seattle,
WA; 2University of Washington, Seattle, WA
The biologic processes underlying cGVHD and the development
of clinical tolerance are unknown. We tested whether gene expres-
sion in CD4+T cells can distinguish between patients with and with-
out active cGVHD. CD4+ T cells from 69 patients and 22 normal
volunteers were isolated by negative selection and RNA analyzed
using Illumina RefSeq8 arrays. Thirty-one patients were tolerant
(defined as free of any chronic GVHDwithout immune suppression
therapy {IST} for at least 6 months), and 38 patients had active
cGVHD (14 with and 22 without IST). A hierarchical clustering
analysis of differentially expressed genes separated the 31 tolerant
patients into 2 groups, and an analysis of clinical covariables demon-
strated that they differed primarily by interval time from HCT (1-5
yrs, and 5-16 yrs). Differential expression was observed for 1148
genes in cGVHD patients, 902 genes in 18 tolerant patients at 1-5
yrs after HCT, and 186 genes in 13 tolerant patients at 5-16 yrs after
HCT compared to controls. We found substantial overlap in the
genes differentially expressed in cGVHD and tolerant groups, espe-
cially early after HCT. The shared cGVHD-tolerant profile was
characterized by activation of NF-kB-associated and IFN-inducible
genes, and upregulation of Th1 pathways. The differentially ex-
pressed genes uniquely associated with the early tolerance after
HCT were associated mainly with protein biosynthesis and metabo-
lism. We found no differential expression of TGFB-associated
genes, IL10 or FOXP3. Fewer genes were differentially expressed
in the late tolerant group compared to the early tolerant group
(186 vs 902), with no consistent qualitative difference in the associ-
ated functions of these genes in late vs. early tolerant profiles. In
summary, in this CD4+ T cell gene expression dataset, we found
no evidence for an expression profile unique to tolerant patients.
The number of genes differentially expressed in tolerant patients re-
turned toward normal over time, but differential expression relative
to age-matched normal controls continued as late as 15 years after
HCT. Future expression studies in function-defined CD4+ T cell
subsets or Tregmay yet provide insight into themechanisms respon-
sible for development of immunological tolerance after HCT.517
ASSOCIATION BETWEEN SERUM HIGH-MOLECULAR-WEIGHT ADIPO-
NECTIN LEVEL AND THE SEVERITY OF CHRONIC GRAFT-VERSUS-HOST
DISEASE IN ALLOGENEIC STEM CELL TRANSPLANTATION RECIPIENTS
Nakasone, H.1, Binh, P.N.T.2,3, Yamazaki, R.1, Tanaka, Y.1,
Sakamoto, K.1, Ashizawa, M.1, Sato, M.1, Terasako, K.1, Kimura, S.-
I.1, Kikuchi, M.1, Kako, S.1, Okuda, S.1, Oshima, K.1, Tanihara, A.1,
Nishida, J.1, Abe, Y.1, Kanda, Y.1 1SaitamaMedical Center, JichiMedicalUniversity, Saitama, Saitama, Japan; 2Cardiovascular Research Institute,
Saitama Medical Center, Jichi Medical University, Saitama, Saitama,
Japan; 3HCMC Nutrition Center, HCMC, Viet Nam
Background: Recently, a growing body of evidence has suggested
that adiponectin, which is secreted by adipose tissues, plays a critical
role in obesity-related and autoimmune diseases. However, the roles
of adiponectin in allogeinc stem cell transplantation remains un-
known. Therefore, we compared the serum adiponectin levels
among allo-SCT recipients and normal subjects to assess the associ-
ation between adiponectin and cGVHD.
Patients and methods: We compared the concentrations of high-
molecular-weight (HMW) adiponectin among 26 normal subjects
and 35 allogeneic stem cell transplantation recipients by an en-
zyme-linked immunosorbent assay. To compareHMW-adiponectin
levels among groups, we used the first samples obtained at least 6
months after SCT. Furthermore, we calculated the ratios of
HMW-adiponectin between each pair of consecutive samples in
the same patients, and assessed the impact of the clinical changes
in cGVHD on HMW-adiponectin concentrations among recipients
grouped according to worsening, stable, and improving cGVHD.
Results: The serum concentrations of HMW-adiponectin in
healthy subjects and recipients without chronic graft-versus-host-
disease (cGVHD), with limited cGVHD, and with extensive
cGVHD were 8.766.5, 10.664.2, 19.1610.7 and 25.969.9 mg/ml
in females (P 5 0.0011), and 3.661.8, 5.364.1, 6.466.7 and
9.966.1mg/ml in males (P 5 0.039). Multivariate analysis revealed
that a higher concentration of adiponectin was associated with fe-
male gender (P \ 0.0001) and the presence of cGVHD (P 5
0.0026 and\0.0001 in limited and extensive cGVHD, respectively).
In addition, HMW-adiponectin levels increased as cGVHD pro-
gressed, decreased as cGVHD improved, and did not change with
stable cGVHD.
Conclusion:HMW-Adiponectin was associated with the severity of
cGVHD, and might play a role in the pathophysiology of
cGVHD.Further investigation is warranted.518
ATG FOR THE PREVENTION OF SEVERE ACUTE GRAFT-VERSUS-HOST
DISEASE IN MISMATCHED UNRELATED DONOR HEMATOPOIETIC CELL
TRANSPLANTATION
Pidala, J., Tomblyn, M., Nishihori, T., Perkins, J., Field, T., Ayala, E.,
Bookout, R., Conwell, M., Perez, L., Ochoa, L., Alsina, M., Shapiro, J.,
Tate, C., Locke, F., Fernandez, H., Anasetti, C. Moffitt Cancer Center,
Tampa, FL
Severe (grade III-IV) acute GVHD remains a major source of
morbidity and mortality following mismatched unrelated donor he-
matopoietic cell transplantation (HCT). As donor alloreactive T
cells are principal mediators of the syndrome, in vivoT cell depletion
by anti-lymphocyte antibodies may offer additional protection
against severe aGVHD. We have developed a regimen of anti-thy-
mocyte globulin (ATG) 7.5mg/kg total (1m/kg day -3, and
3.25mg/kg on days -2 and -1) to both minimize toxicity from oppor-
tunistic infections and optimize efficacy in aGVHD prevention. We
identified a consecutive series of 6-7/8 mismatched (at loci A, B, C,
DR) unrelated donor HCT recipients treated with 7.5mg/kg total
(1mg/kg given day -3, then 3.25mg/kg/day on days -2 and -1) rabbit
ATG in concert with calcineurin inhibitor-based pharmacologic
GVHD prophylaxis prior to stem cell infusion. Forty-five subjects
were included in this analysis; seven subjects treated with this regi-
men were excluded, given sole mismatch at DQ (n5 4) or 8/8 match
(n 5 3). Median age of subjects was 48 (range 22 – 67). There was
disparity at heterogeneous HLA loci between recipient and donor,
including mismatch at one locus in 43 cases and two loci in 2 cases.
There were no cases of primary engraftment failure. Neutrophil
(median 15 days, range 11 – 25) and platelet (median 16 days, range
7 – 31) engraftment were not delayed. The cumulative incidence of
grade III-IV acute GVHD was 11% by 100 days (95% CI 5 –
25%). Moderate to severe chronic GVHD (per NIH criteria) was
19% (95% CI 10 – 36%) at one year, and 28% (95% CI 16 –
48%) at 2 years. With a median follow up of 12 months (range 5 –
39 months), overall survival was 55% (95% CI 39 – 71%) at one
year, and 45% (95%CI 27 – 63%) at two years. Non-relapse mortal-
ity was 11% (95% CI 5 – 25%) by 100 days post-HCT, and 26%
